Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
20ND02 by HK inno.N for Glaucoma: Likelihood of Approval
20ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II...
Data Insights
20ND02 by HK inno.N for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
20ND02 is under clinical development by HK inno.N and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...